Residential College | false |
Status | 已發表Published |
Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor | |
Li, Ting1; Chen, Xin1; Dai, Xiao-Yang2; Wei, Bin1; Weng, Qin-Jie2; Chen, Xiuping1; Ouyang, De-Fang1; Yan, Ru1; Huang, Zhang-Jian3; Jiang, Hu-Lin3; Zhu, Hong2; Lu, Jin-Jian1 | |
2017-09 | |
Source Publication | TOXICOLOGY AND APPLIED PHARMACOLOGY |
ISSN | 0041-008X |
Volume | 330Pages:65-73 |
Abstract | Heat shock protein 90 (Hsp90) is a critically conserved molecular chaperone protein and promising therapeutic target for cancer treatment. In this study, platycodin D (PD), a saponin isolated from traditional Chinese herb Platycodonis Radix, was identified as a novel Hsp90 inhibitor. We verified that PD did not affect the ATPase activity of Hsp90. However, PD disrupted the co-chaperone interaction of Hsp90/cell division cycle protein 37 (Cdc37) and subsequently degraded multiple Hsp90 client proteins without the feedback increase of Hsp70. In different genotypes of non -small cell lung cancer cells, co-treatment with the mTOR inhibitor Everolimus and PD enhanced antiproliferation activity and apoptotic effect. The feedback survival signal upon mTOR inhibition was fully terminated by the co-administration with PD through reduced epidermal growth factor receptor (EGFR) and insulin growth factor 1 receptor (IGF1R) expression, suppressed AKT activity, and reinforced 4E-BP1 inhibition. Our results not only identified PD as a novel Hsp90 inhibitor by disrupting the protein-protein interaction of Hsp90/Cdc37 complex, but also provided mechanistic insights into the ineffectiveness of mTOR inhibitors and identified therapeutic strategy for cancer treatment. (C) 2017 Elsevier Inc. All rights reserved. |
Keyword | Everolimus Platycodin d Hsp90 Cdc37 Egfr Igf1r |
DOI | 10.1016/j.taap.2017.07.006 |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Pharmacology & Pharmacy ; Toxicology |
WOS Subject | Pharmacology & Pharmacy ; Toxicology |
WOS ID | WOS:000407662600008 |
Publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE |
The Source to Article | WOS |
Scopus ID | 2-s2.0-85025070666 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | DEPARTMENT OF PHARMACEUTICAL SCIENCES Institute of Chinese Medical Sciences THE STATE KEY LABORATORY OF QUALITY RESEARCH IN CHINESE MEDICINE (UNIVERSITY OF MACAU) |
Corresponding Author | Lu, Jin-Jian |
Affiliation | 1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China 2.College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China 3.State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China |
First Author Affilication | Institute of Chinese Medical Sciences |
Corresponding Author Affilication | Institute of Chinese Medical Sciences |
Recommended Citation GB/T 7714 | Li, Ting,Chen, Xin,Dai, Xiao-Yang,et al. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 330, 65-73. |
APA | Li, Ting., Chen, Xin., Dai, Xiao-Yang., Wei, Bin., Weng, Qin-Jie., Chen, Xiuping., Ouyang, De-Fang., Yan, Ru., Huang, Zhang-Jian., Jiang, Hu-Lin., Zhu, Hong., & Lu, Jin-Jian (2017). Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. TOXICOLOGY AND APPLIED PHARMACOLOGY, 330, 65-73. |
MLA | Li, Ting,et al."Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor".TOXICOLOGY AND APPLIED PHARMACOLOGY 330(2017):65-73. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment